Testing EGFR drugs before lung surgery in certain stage III cancers
Treatments studied
Part of Cancer clinical trials.
This trial tests whether taking furmonertinib alone, or furmonertinib plus bevacizumab, before surgery can improve outcomes for people with EGFR-mutated lung adenocarcinoma that has not spread to distant organs. It may help shrink the tumor and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung cancer is adenocarcinoma with an EGFR “sensitive” mutation proven by biopsy
- Your cancer is stage III-IVA (not early stage), based on scans like CT/PET-CT and/or EBUS
- There is no evidence of spread to distant organs on tests like brain MRI and whole-body scans
- Your medical team thinks you can safely have curative surgery (lung lobectomy plus lymph node removal)
- Your general health is good enough for treatment and surgery (lung function, labs, and ECOG 0–1)
- If you can become pregnant, you must have a negative pregnancy test and use reliable birth control; if you’re male, you must use condoms
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a strong dose of furmonertinib (a targeted pill) combined with two other drugs, bevacizumab and pemetrexed, for people with EGFR-mutated non-small cell lung cancer that has spread to the lining of the brain or spinal cord. It aims to see if this combination can better control the cancer and improve symptoms.
This trial tests giving Furmonertinib (an oral targeted therapy) before surgery to shrink tumors in people with a specific EGFR gene mutation in their non-small cell lung cancer. The goal is to make surgery more effective and improve outcomes.
This trial tests whether taking furmonertinib before surgery can help shrink tumors in people with early-stage EGFR-mutant lung cancer. It aims to improve surgical outcomes and long-term results.
This trial tests a combination of two targeted medicines (befotertinib and bevacizumab) before surgery for people with EGFR-mutant non-small cell lung cancer that cannot be removed right away. The goal is to see if this treatment can shrink the tumor and improve surgery outcomes.
This trial tests whether furmonertinib, an oral targeted medicine, can improve outcomes after your lung tumor has been completely removed. It also checks for side effects and compares results against placebo in people with specific EGFR gene mutations.
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
Hear when a new EGFR Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.